Evidence map›Paper›PMID 42794865›Full record

ArticleCancers2026

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL-A Case-Matched Retrospective Analysis of the Polish Adult Leukemia Group (PALG).

Agnieszka Pluta, Damian Mikulski, Marta Sobas, Kinga Strzałka, Magdalena Czemerska, Dominika Trybunia-Orzeszek, Tomasz Wrobel, Bozena Budziszewska, Marzena Wątek, Ewa Lech-Maranda and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Agnieszka PlutaDepartment of Hematology, Medical University of Lodz, 90-419 Lodz, Poland.
Damian MikulskiThe Nicolas Copernicus Multidisciplinary Provincial Center of Traumatology and Oncology, 93-513 Lodz, Poland.ORCID 0000-0002-2806-2583
Marta SobasDepartment of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Piast Medical University, 50-367 Wroclaw, Poland.
Kinga StrzałkaDepartment of Hematology, Medical University of Lodz, 90-419 Lodz, Poland.
Magdalena CzemerskaDepartment of Hematology, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0002-8033-4662
Dominika Trybunia-OrzeszekThe Nicolas Copernicus Multidisciplinary Provincial Center of Traumatology and Oncology, 93-513 Lodz, Poland.
Tomasz WrobelDepartment of Hematology, Blood Neoplasm and Bone Marrow Transplantation, Piast Medical University, 50-367 Wroclaw, Poland.
Bozena BudziszewskaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.ORCID 0000-0002-9482-4099
Marzena WątekDepartment of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Ewa Lech-MarandaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
Tomasz GromekDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-080 Lublin, Poland.
Dorota HawryleckaDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-080 Lublin, Poland.
Marek HusDepartment of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, 20-080 Lublin, Poland.
Ewa ZarzyckaDepartment of Hematology and Transplantation, Medical University of Gdansk, 80-952 Gdansk, Poland.
Jan Maciej ZauchaDepartment of Hematology and Transplantation, Medical University of Gdansk, 80-952 Gdansk, Poland.ORCID 0000-0002-0986-8936
Anna ArmatysDepartment of Hematology and Bone Marrow Transplantation, Medical School of Silesia, 40-032 Katowice, Poland.
Grzegorz HelbigDepartment of Hematology and Bone Marrow Transplantation, Medical School of Silesia, 40-032 Katowice, Poland.ORCID 0000-0003-3703-1268
Jolanta OleksiukDepartment of Hematology, Medical University Hospital, 15-276 Bialystok, Poland.ORCID 0009-0003-4185-8492
Łukasz BołkunDepartment of Hematology, Medical University Hospital, 15-276 Bialystok, Poland.
Andrzej SzczepaniakDepartment of Hematology, Transplantation and Cellular Therapy, Poznan University of Medical Sciences, 60-569 Poznan, Poland.ORCID 0000-0002-1732-8964
Lidia GilDepartment of Hematology, Transplantation and Cellular Therapy, Poznan University of Medical Sciences, 60-569 Poznan, Poland.
Rafał BechtClinical Department of Oncology, Chemotherapy and Cancer Immunotherapy, Pomeranian Medical University, 71-252 Szczecin, Poland.
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 93-510 Lodz, Poland.
Sebastian GiebelDepartment of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute-Cancer Center, Gliwice Branch, 44-101 Gliwice, Poland.
Agnieszka WierzbowskaDepartment of Hematology, Medical University of Lodz, 90-419 Lodz, Poland.ORCID 0000-0001-7909-457X

Funding

Medical University of Lodz 503/1-093-01/503-11-001
6 · The paper itself

Abstract

backgroundSecondary acute promyelocytic leukemia (sAPL) is a very rare subtype of acute myeloid leukemia that develops following exposure to chemotherapy, radiotherapy, or immunosuppressive agents. The treatment results and survival outcomes of sAPL patients are still not precisely defined.

methodsA search of the Polish Adult Leukemia Group (PALG) database identified 29 cases of sAPL (median age 57 years; 62.1% female) among 437 APL patients (6.7%) diagnosed between 2006 and 2024. Each sAPL case was matched to a de novo APL patient by sex, age, year of diagnosis, and treatment protocol (LPA (Leucemia Promielocítica Aguda) 2005, LPA 2012, or LPA 2017).

resultsAll sAPL cases occurred following chemo- and/or radiotherapy, most commonly for breast cancer. The sAPL cases demonstrated higher CD15 expression than the de novo APL cases (median 27.6% vs. 7%,

conclusionsThese findings suggest that sAPL shares many clinical features with de novo APL but carries a higher risk of relapse, highlighting the need for further prospective studies and the potential implementation of tailored therapeutic strategies.

Indexed as

CD15de novo APLsecondary APLtreatment

Identifiers

PMID42794865
PMCPMC13604275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.